SUMMARY The transmucosal electrical potential difference (pd) and the sodium and potassium net fluxes were measured in the rectum of subjects taking carbenoxolone. There was a rise in transmucosal pd persisting throughout treatment in all subjects which was accompanied by an increase in sodium absorption and potassium secretion. Comparison of the pd changes produced by carbenoxolone with those due to the mineralocorticoid 9-a-fluorocortisol showed that carbenoxolone had about 1/1000th the potency on a weight basis and the two drugs appeared to be additive in their effects. Topical instillation of carbenoxolone into the rectum produced an elevation of pd which persisted for three days. Amiloride Vries, and Molhuysen, 1953) . The mechanism of the production of the hypokalaemia has not been fully explained since it has usually been difficult to demonstrate much increase in potassium loss in the urine (Baron and Nabarro, 1968; Wynn, 1968; MacKay, 1968 the pd rose during carbenoxolone therapy. In the present paper, we describe the effects of carbenoxolone therapy on the rectal pd in patients with peptic ulcer and in normal volunteers together with the influence of various diuretics. We have also studied the effect of carbenoxolone on the sodium and potassium net fluxes using the dialysis method (Edmonds, 1971) and on the ions in faecal water.
the pd rose during carbenoxolone therapy. In the present paper, we describe the effects of carbenoxolone therapy on the rectal pd in patients with peptic ulcer and in normal volunteers together with the influence of various diuretics. We have also studied the effect of carbenoxolone on the sodium and potassium net fluxes using the dialysis method (Edmonds, 1971 ) and on the ions in faecal water.
Methods

PATIENTS AND NORMAL INDIVIDUALS
The principal studies were performed on nine patients with peptic ulcer (six had gastric ulcer and three had duodenal ulcer) and two normal individuals. Eight of these patients, aged 19-65 years, were otherwise healthy with no clinical or laboratory evidence of cardiac, renal, or hepatic disease, and blood pressure and serum electrolytes were all normal at the start of the study. Each patient was studied before, during, and after a six-week course of carbenoxolone sodium using 100 mg three times daily for one week followed by 50 mg three times daily for five weeks. All these individuals were outpatients and at each clinic attendance body weight, blood pressure, serum potassium, total body potassium (K40), and transmucosal pd were recorded. A further patient was investigated (W.B., a 62-year-old man with a gastric ulcer) who developed fluid retention while taking carbenoxolone. He had been previously fit with normal exercise tolerance and at the initial physical examination chest radiographs and biochemical screening showed no abnormality. In the outpatient trial, he gained an undue amount of weight during the first week of carbenoxolone treatment and the drug was discontinued. In view of continuing peptic ulcer symptoms, he was admitted two weeks later and the trial of carbenoxolone was carried out during his inpatient stay.
Two healthy volunteers were also investigated while taking varying doses of carbenoxolone and intermittently bendrofluazide or spironolactone. They continued normal activities throughout the period of investigation.
TRANSMUCOSAL ELECTRICAL PD
The pd was measured using a probe electrode constructed from a perspex (lucite) tube which contained an Ag-AgCl junction in contact with a short column of saline-agar (150 mmol/1-4%Y agar). The skin electrode, which was also constructed from perspex, contained a Ag-AgCl junction and saline agar and was applied to a bleb produced by the intradermal injection of sterile isotonic sodium chloride solution (Archampong and Edmonds, 1972 to the transmucosal Ipd. The asymmetry pd of the electrode system was always checked before and after measurements and any necessary correction made. Measurements of pd were recorded on the mucosa at about 8 to 10 cm from the anus.
FLUX MEASUREMENTS
Dialysis tubes (Visking, diameter 0 5 cm, length 8 cm) mounted on rubber catheters and containing 1 6 ml of solution were used. Full details of this method with its evaluation and calculations used to estimate flux rates have previously been described (Edmonds, 1971 
Normal individuals
The transmucosal pd, measured on a number of different occasions before treatment began, showed a considerable difference between the two ,individuals but the measurements in each were consistent and the mean pd of both was within our established range for normals (34 ± 6 mV SD from 24 normal individuals). Comparison of the response of pd to various treatment regimens was examined (fig 2) . 9-oc-Fluorocortisol, a potent mineralocorticoid, taken orally in doses of 01 mg or 0-2 mg daily for three days, produced a rise in pd, the values shown being those found on the third day. It has been shown previously that the pd does not alter significantly if the drug is continued for a longer period (Edmonds and Richards, 1970) . Carbenoxolone given for five days produced a rise in pd by the fifth day. With carbenoxolone 150 mg daily there was significant elevation in subject A (p < 0 05), but, although pd rose in subject B, the change did not achieve significance. With carbenoxolone 300 mg daily the increase in pd was significant (<0 05) in both subjects, the rise being approximately equivalent to that produced by 0-2 mg of 9-a-fluorocortisol. To see how carbenoxolone and 9-oc-fluorocortisol behaved when taken together, carbenoxolone 150mgdaily was given Transmucosal pd (mV) for five days and 9-oc-fluorocortisol 0-1 mg daily was added for the last three days. The elevation of pd when measured on the fifth day ofcarbenoxolone was similar to that observed when carbenoxolone 300 mg daily or 9-a-fluorocortisol 0-2 xmg daily was given alone. The effects of the two substances as judged by rectal pd did therefore appear to be additive; there was no evidence of potentiation or antagonism. The influence of the diuretics bendrofluazide and spironolactone on the carbenoxolone action was examined in the normal individuals, the diuretics being given over the last two days of a five-day course of carbenoxolone 300 mg daily. Bendrofluazide, 10 mg daily, did not interfere with the rise in pd produced by carbenoxolone but when spironolactone 200 mg daily was taken the pd was considerably reduced (fig 2) , indicating that spironolactone prevented completely the increase of pd which otherwise occurs during carbenoxolone therapy. Both diuretics produced a diuresis and reversed the weight gain produced by carbenoxolone alone.
Topical application
In animal experiments, aldosterone has been shown to be effective in altering pd only when it is applied to the serosal surface and practically without action when in the lumen of the gut (Edmonds and Marriott, 1969) . The effect of carbenoxolone applied directly to the mucosal side of the epithelium was examined in two normal individuals, carbenoxolone dissolved in 20 ml of normal saline being given by rectal enema. In both subjects a rise in transmucosal pd evident within a few hours and the change persisted for three days (fig 3) . The results illustrated were from one of the normal individuals obtained from four separate experiments and given as means ± SEM. The effects ofaddition of bendrofluazide and spironolactone were each studied on two occasions and the mean result is shown.
I there were increases in sodium absorption and potassium secretion which were significant in both individuals. Similar results were obtained using solution IT with a significant increase in sodium absorption in both individuals and a significant increase in potassium secretion in one.
Discussion
The mucosal epithelium of the distal colon and rectum is responsible for active transport of sodium whereby ions are moved from lumen to blood against an ionic concentration gradient (Edmonds, 1971) . This active transfer of sodium ions appears to be largely responsible for the observed transmucosal pd (Cooperstein and Hogben, 1959) . Associated with the increase in sodium absorption and in potassium secretion produced by mineralocorticoids, such as aldosterone and 9-oc-fluorocortisol, is a marked increase in the pd (Edmonds and Godfrey, 1970;  Edmonds, 1972; Efstratopoulos, Peart, and Wilson, 1974) so that rectal pd can be a simple index of mineralocorticoid activity. Carbenoxolone sodium is synthesized from glycyrrhizic acid, one of the constituents of liquorice. Bothliquoriceandcarbenoxolone can produce effects-fluid retention and hypokalaemia-similar to those occurring with high doses of mineralocorticoids. The present study showed that the action of .
. . carbenoxolone on the bowel was similar to that of mineralocorticoids like aldosterone. The rise in pd, the increase in sodium absorption and in potassium secretion, together with the blocking of these effects by spironolactone, are all characteristic (Levitan and Ingelfinger, 1965; Shields et al, 1966; Richards, 1969; Edmonds, 1972) . The rise in pd occurred in all of the individuals given the drug indicating that the mineralocorticoid action is not confined to those who have overt side effects. There are several ways in which this action might be produced by carbenoxolone and these are best considered in relation to the effects of aldosterone itself. Aldosterone appears to bind to a cytosol receptor and promote, through the DNA-RNA-ribosome system, the formation of specific proteins responsible for the changes in sodium and potassium transport (Edelman and Fimognari, 1968) . One possibility is that carbenoxolone simply acts like aldosterone itself in this system, binding with the receptors and promoting the production of the specific proteins. Thus here carbenoxolone would be considered as a mineralocorticoid-type agent like 9-ao-fluorocortisol, for example, although apparently much weaker since on the basis of our findings, the latter is, on a weight basis, practically a thousandfold more potent than carbenoxolone. Alternatively, since carbenoxolone has strong affinity for serum and tissue proteins, it may produce its mineralocorticoid effects by displacing aldosterone from binding proteins thus allowing more free aldosterone to react with the specific receptor sites. From the present study, showing that carbenoxolone is effective in low dose when applied directly to the luminal side of rectal mucosa, it can be concluded that displacement of aldosterone from serum proteins by carbenoxolone is not responsible for this mineralocorticoid effect. However, other possibilities remain, for example, that carbenoxolone may displace aldosterone from non-specific protein-binding sites within the cells or affect aldosterone action at a cellular level. All individuals taking carbenoxolone showed evidence of excessive mineralocorticoid activity as judged by the changes observed in the bowel mucosa. The pd remained elevated for as long as the carbenoxolone was taken, a finding similar to that observed during prolonged 9-oc-fluorocortisol administration and in patients with hyperaldosteronism (Edmonds and Richards, 1970) . The bowel, unlike the kidney, does not 'escape' from the mineralocorticoid effects. In various pathological states and in some normal individuals, the renal 'escape' mechanism appears not to operate so that a continuing positive sodium balance leads to oedema formation. The pd measured in the one patient who developed considerable salt and water retention was 3* not significantly different from values found in the other patients who had no side effects, suggesting that the active sodium absorption mechanism was under similar stimulation and that the development of fluid retention in that patient was the result of failure of renal 'escape'. The studies made with diuretics showed that spironolactone could completely abolish the mineralocorticoid activity of carbenoxolone. Spironolactone should therefore be the ideal agent in preventing side effects but unfortunately it seems also to interfere with the efficacy of carbenoxolone in healing gastric ulcers (Doll, Langman, and Shawdon, 1968) and so cannot be used. Both the other diuretics used, one a thiazide drug, bendrofluazide, and the other, amiloride, did not affect the mineralocorticoid action of carbenoxolone on the bowel. Amiloride would be expected to be useful in preventing the side effects of carbenoxolone because it acts on the distal renal tubule to reduce sodium absorption and potassium secretion although it is not a competitor of mineralocorticoids (Baer, Mucha, Spitzer, and Yee, 1966) . Therefore while it is a relatively weak diuretic, it does reduce potassium loss and so is valuable in avoiding hypokalaemia and total body potassium depletionwhen there is excessive mineralocorticoid activity, for example, in hyperaldosteronism or when carbenoxolone is used (Reynolds and Pelle, 1966; Alter, Cushman, and Hilton, 1967; Braren, Campbell, Hashim, and Van Hallie, 1968; Edmonds and Tomkins, 1975) . Its influence on the healing properties of carbenoxolone has not been tested, but, since it is quite different from spironolactone in its mode of action, it seems unlikely that it would interfere with the therapeutic action of carbenoxolone.
In conclusion, it appears from this study that carbenoxolone consistently produces mineralocorticoid activity in the rectal mucosa of all individuals taking the drug. This action of carbenoxolone does not depend on displacement ofaldosterone from serum proteins but may reflect an inherent mineralocorticoid property of carbenoxolone. This mineralocorticoid effect is antagonized by spironolactone but not by bendrofluazide or amiloride and the latter drug may be of value in treating fluid retention during carbenoxolone therapy because of its potassium-sparing action which is not due to aldosterone antagonism.
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